Showing results (91-100 of 155) with videos related to

Sort By:
Pageof 16
Cancer Medicine|July 6, 2024
Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumorsAgostina Stradella, Melissa Johnson, Sanjay Goel, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2021
Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynxCaroline Hoffmann, Valentin Calugaru, Edith Borcoman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumorsJonathan Goldman, S Gail Eckhardt, Mitesh J Borad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2019
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid TumorsRastislav Bahleda, Antoine Italiano, Cinta Hierro, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancerThomas Wehler, Michael Thomas, Christian Schumann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2018
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric CancerYelena Y Janjigian, Johanna Bendell, Emiliano Calvo, et al.
Investigational New Drugs|November 28, 2017
Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trialEmiliano Calvo, Analia Azaro, Jordi Rodon, et al.
BMC Cancer|February 17, 2017
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patientsBerta Laquente, Jose Lopez-Martin, Donald Richards, et al.
Investigational New Drugs|June 20, 2014
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancerEmiliano Calvo, Victor J Chen, Mark Marshall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2024
Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell ResponsesAnna Morena D'Alise, Guido Leoni, Gabriella Cotugno, et al.
Pageof 16